Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ProPhase Labs (PRPH) Shares Outstanding (Diluted Average): 2011-2025

Historic Shares Outstanding (Diluted Average) for ProPhase Labs (PRPH) over the last 13 years, with Sep 2025 value amounting to $41.5 million.

  • ProPhase Labs' Shares Outstanding (Diluted Average) rose 117.73% to $41.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.5 million, marking a year-over-year increase of 117.73%. This contributed to the annual value of $20.5 million for FY2024, which is 18.92% up from last year.
  • According to the latest figures from Q3 2025, ProPhase Labs' Shares Outstanding (Diluted Average) is $41.5 million, which was down 0.00% from $41.5 million recorded in Q2 2025.
  • ProPhase Labs' 5-year Shares Outstanding (Diluted Average) high stood at $41.5 million for Q2 2025, and its period low was $15,154 during Q2 2021.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $23.9 million, with a median of $18.9 million in 2024.
  • In the last 5 years, ProPhase Labs' Shares Outstanding (Diluted Average) tumbled by 99.84% in 2021 and then skyrocketed by 131,048.39% in 2022.
  • ProPhase Labs' Shares Outstanding (Diluted Average) (Quarterly) stood at $18.4 million in 2021, then grew by 1.40% to $18.7 million in 2022, then fell by 7.74% to $17.2 million in 2023, then increased by 18.92% to $20.5 million in 2024, then spiked by 117.73% to $41.5 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $41.5 million for Q3 2025, versus $41.5 million for Q2 2025 and $35.2 million for Q1 2025.